Home > Press > UCLA and Japan Collaborate on Drug-Delivery
Abstract:
The California NanoSystems Institute at UCLA has announced a new collaboration with Japan-based NOF Corp. to explore initiatives in nanotherapeutics research for new drug-delivery systems.
"CNSI is committed to strong and productive collaborations with industry," says Paul Weiss, CNSI director and UCLA's Fred Kavli Chair in Nanosystems Sciences. "We look forward to working with the researchers at NOF's Drug Delivery Systems Development Division."
"We are delighted to collaborate with the stellar group of investigators at CNSI and UCLA on shared interests in new methods and materials for drug delivery," says Akiharu Kobayashi, director and operating officer of NOF and general manager of the company's Drug Delivery Systems (DDS) Development Division.
The collaboration agreement between the CNSI and NOF, signed on Dec. 15 by Weiss and Kobayashi, also marks the beginning of the Frontier Research Program, an industry-affiliated research initiative at the CNSI.
The program is designed to promote close interdisciplinary research collaborations between diverse industries and researchers at UCLA and focuses on novel technologies for the nanodelivery of drug therapies. In the future, the Frontier program aims to cover activities in three main areas of research: information technology, including nanolectronics, computation and information technology; green technology, including water, solar and other technologies; and human health and the environment, including nanomedicine, health care devices and nano-safety.
####
About California NanoSystems Institute
The California NanoSystems Institute at UCLA is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; to train the next generation of scientists, educators and technology leaders; and to facilitate partnerships with industry, fueling economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding. At the institute, scientists in the areas of biology, chemistry, biochemistry, physics, mathematics, computational science and engineering are measuring, modifying and manipulating the building blocks of our world — atoms and molecules. These scientists benefit from an integrated laboratory culture enabling them to conduct dynamic research at the nanoscale, leading to significant breakthroughs in the areas of health, energy, the environment and information technology.
About NOF
NOF Corp., headquartered in Tokyo, was incorporated in 1937 and has become Japan's leading oleochemicals group, producing a highly diversified range of products. NOF pursues multi-faceted business development in eight divisions, based on its own technologies, with the aim of creating new values in a broad spectrum. The company focuses in particular on the areas of life sciences, electronics and information, and energy and the environment.
For more information, please click here
Contacts:
www.cns-inc.com/contact.cfm
Copyright © UCLA
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||